/institutions/newsroom/ 15/?source= Latest news from University of Texas M. D. Anderson Cancer Center on Newswise en-us Copyright 2022 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/view/784413/?sc=rsin /articles/view/784413/?sc=rsin Wed, 21 Dec 2022 17:00:00 EST In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center. University of Texas M. D. Anderson Cancer Center /articles/view/784204/?sc=rsin /articles/view/784204/?sc=rsin Mon, 19 Dec 2022 12:00:34 EST The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world's largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury. University of Texas M. D. Anderson Cancer Center /articles/view/783753/?sc=rsin /articles/view/783753/?sc=rsin Mon, 12 Dec 2022 12:00:00 EST Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). University of Texas M. D. Anderson Cancer Center /articles/view/783778/?sc=rsin /articles/view/783778/?sc=rsin Fri, 09 Dec 2022 10:00:20 EST This special edition features presentations by MD Anderson researchers at the 2022 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches and novel targets to improve outcomes for patients with leukemias, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma and other hematologic cancers. University of Texas M. D. Anderson Cancer Center /articles/view/783636/?sc=rsin /articles/view/783636/?sc=rsin Wed, 07 Dec 2022 11:00:00 EST Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, has received a 2022 ASH Mentor Award from the American Society of Hematology in acknowledgement of his career-long commitment to mentoring. University of Texas M. D. Anderson Cancer Center /articles/view/783462/?sc=rsin /articles/view/783462/?sc=rsin Mon, 05 Dec 2022 11:00:00 EST The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features breast cancer presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS) focused on the combination of everolimus and hormone therapy, a new driver for brain metastases in inflammatory breast cancer, improving treatment for men with breast cancer, and a new understanding of the importance of HER2 expression for patients with early-stage triple-negative breast cancers. University of Texas M. D. Anderson Cancer Center /articles/view/783160/?sc=rsin /articles/view/783160/?sc=rsin Wed, 30 Nov 2022 12:00:20 EST The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. University of Texas M. D. Anderson Cancer Center /articles/view/782572/?sc=rsin /articles/view/782572/?sc=rsin Wed, 16 Nov 2022 15:00:29 EST The University of Texas MD Anderson Cancer Center today announced a $10 million gift to the James P. Allison Institute from the Andrew Sabin Family Foundation and Andrew "Andy" Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors (BOV). The gift is the philanthropist's second multimillion-dollar commitment to MD Anderson in less than 10 years. University of Texas M. D. Anderson Cancer Center /articles/view/782477/?sc=rsin /articles/view/782477/?sc=rsin Wed, 16 Nov 2022 14:00:00 EST The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising targeted therapy combination for patients with relapsed/refractory acute myeloid leukemia (AML), a link between the gut microbiome and therapy-related neutropenic fever, a novel therapeutic target for immunotherapy-related colitis, a telementoring model for training providers on cervical cancer prevention in limited-resource areas, a new understanding of the prognostic value of RUNX1 mutations in AML, and insights into the effects of opioid use on the pain sensitivity pathway. University of Texas M. D. Anderson Cancer Center /articles/view/782319/?sc=rsin /articles/view/782319/?sc=rsin Mon, 14 Nov 2022 07:00:18 EST MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies. University of Texas M. D. Anderson Cancer Center /articles/view/782278/?sc=rsin /articles/view/782278/?sc=rsin Fri, 11 Nov 2022 12:55:12 EST Eyal Gottlieb, Ph.D., has been named MD Anderson's vice president for Research. Gottlieb, an accomplished scientist and leader, will join the institution in January to uphold and expand the institution's research excellence. University of Texas M. D. Anderson Cancer Center /articles/view/782139/?sc=rsin /articles/view/782139/?sc=rsin Thu, 10 Nov 2022 10:00:00 EST A team of researchers at The University of Texas MD Anderson Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types. University of Texas M. D. Anderson Cancer Center /articles/view/782018/?sc=rsin /articles/view/782018/?sc=rsin Tue, 08 Nov 2022 17:00:55 EST This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer. University of Texas M. D. Anderson Cancer Center /articles/view/781730/?sc=rsin /articles/view/781730/?sc=rsin Fri, 04 Nov 2022 19:30:00 EST Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center. University of Texas M. D. Anderson Cancer Center /articles/view/781711/?sc=rsin /articles/view/781711/?sc=rsin Thu, 03 Nov 2022 12:30:05 EST Thousands are expected at MD Anderson's Boot Walk to End Cancer(r) on Saturday, Nov. 5, as The University of Texas MD Anderson Cancer Center prepares for the in-person return of the seventh annual event in the Texas Medical Center. University of Texas M. D. Anderson Cancer Center /articles/view/781693/?sc=rsin /articles/view/781693/?sc=rsin Thu, 03 Nov 2022 11:00:43 EST The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. University of Texas M. D. Anderson Cancer Center /articles/view/781562/?sc=rsin /articles/view/781562/?sc=rsin Wed, 02 Nov 2022 14:00:00 EST A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients. University of Texas M. D. Anderson Cancer Center /articles/view/781192/?sc=rsin /articles/view/781192/?sc=rsin Thu, 27 Oct 2022 14:20:26 EST The University of Texas MD Anderson Cancer Center today announced that the Timken Foundation of Canton, Ohio, has made a $5 million commitment to support the James P. Allison Institute at MD Anderson. The gift will support the recruitment of top minds from around the world to help realize the Allison Institute's goals. By establishing a diverse and inclusive environment of scientists from many fields, the Allison Institute will drive exceptional research that integrates immunobiology across disciplines to develop a comprehensive understanding of the immune system. University of Texas M. D. Anderson Cancer Center /articles/view/781150/?sc=rsin /articles/view/781150/?sc=rsin Thu, 27 Oct 2022 12:10:27 EST In recognition of her trailblazing work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina "Gigi" Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected to receive the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association of American Medical Colleges (AAMC). University of Texas M. D. Anderson Cancer Center /articles/view/780871/?sc=rsin /articles/view/780871/?sc=rsin Wed, 26 Oct 2022 11:00:00 EST Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers from The University of Texas MD Anderson Cancer Center reported in Nature. University of Texas M. D. Anderson Cancer Center